Reata Pharmaceuticals Inc diskutieren

Reata Pharmaceuticals Hits A Double With 2 Positive Mid-Stage Results For Chronic Kidney Disease

Reata Pharmaceuticals obtains positive results for both phase 2 studies dealing with two rare forms of chronic kidney disease.

Both phase 2 studies were shown to greatly increase eGFR, which bodes well for incoming late-stage studies.

Phase 2 Data for Alport Syndrome study reveal that bardoxolone has the potential for accelerated approval which should greatly speed up FDA approval.

Both Alport Syndrome and Autosomal dominant polycystic kidney disease only have treatments that take care of the symptoms, however, bardoxolone has the ability treat the diseases themselves.

The financials are in good shape now because Reata has increased its term loan facility to $125 million, and just announced it would sell 3 million shares of its Class A common stock.

Update: Oct. 14, 2019   Reata Pharmaceuticals (NASDAQ:RETA) announces positive results from the registrational portion of its Phase 2 clinical trial, MOXIe, evaluating omaveloxolone in patients with a rare inherited neurodegenerative disorder called Friedreich's ataxia (FA).
The study met the primary endpoint of the change in the modified FA Rating Scale (mFARS) at week 48 versus placebo. The treatment effect was time-dependent with the most significant improvement observed after 48 weeks.